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Abstract 
Nigeria having approximately 50,000 Rotavirus A (RVA) deaths annually is yet to introduce 
RVA vaccine into routine national immunization; therefore surveillance of RVA strains 
circulating before vaccine introduction is essential in evaluating impact of the intervention. 
Stool samples and sociodemographic data of diarrhoeic children, <5 years were collected 
between August 2012 and December 2013. While a high prevalence of RVA infection 
(47.6%; 49/103) was observed by quantitative reverse transcription real time PCR, only 25% 
(26/103) had high RVA genome concentrations and were antigen positive. G and P types were 
obtained for 31 and 37 samples respectively. G12P[8] strains were predominant (30.6%; 
16/31); Other genotypes found included G9, G3, G2 and P[4], P[6], P[8]. A 
G12+G2/P[8]+P[6] mixed infection was detected. The P[8] genotype showed divergence with 
strains distributed in lineage III and IV. Compared to the vaccines, changes in antigenic sites 
of VP8* and VP7 were found. The finding of the G2P[6] genotype combination and 
emergence of G12 strains support observations in most of the recent RVA studies from 
Africa. P[6] is common in many African countries, in contrast to countries in Europe and the 
Americas.  In conclusion, this study shows the circulation of other RVA genotypes compared 
to the common RVA genotypes in Nigeria. PCR results should be interpreted with caution to 
avoid significant bias from samples with low RVA genome concentrations. 
These findings provide important information on the detection and molecular epidemiology of 
RVA prior to vaccination and contribute as a baseline for future evaluations after possible 
vaccine introduction.  
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Introduction 
Group A rotavirus (RVA) is the most common cause of severe diarrhea in infants and young 
children worldwide.
1
 RVA gastroenteritis accounts for approximately one third of the total 
diarrhea deaths worldwide. According to the World Health Organization (WHO), 215,000 
(95% CI 197,000-233,000) children die annually from RVA infection and five countries 
(India, Nigeria, Pakistan, the Democratic Republic of the Congo, and Angola) accounted for 
more than half of all RVA deaths in children under 5 years of age.
1
 In Nigeria, it is estimated 
that approximately 30,000 RVA deaths occur each year. 
Rotavirus forms a genus of the family Reoviridae and is characterized by a segmented double-
stranded RNA genome.
2
 At present, rotaviruses are classified into nine groups (RVA-RVI) 
based on genetic variability of VP6 protein of which only group A, B, C and H rotaviruses 
have been found to infect humans;
3-5
 RVA is the most common. The two outermost proteins, 
VP4 (protease sensitive protein) and VP7 (glycoprotein), specify the P and G genotypes, 
respectively.
2
 At present, 32 G and 49 P genotypes have been identified 
(http://rega.kuleuven.be/cev/viralmetagenomics/virus-classification). The circulating RVA 
strains detected in Nigeria include G1–G4, G8, G9, G10 and G12 detected in 2012.
6-12
 
Two oral live-attenuated RVA vaccines RotaTeq
®
 (RV5) (Merck & Co., Inc., USA) and 
Rotarix
® 
(RV1) (GlaxoSmithKline Biologicals, Belgium) have been licensed in many 
countries around the world. Although the WHO recommends universal inclusion of RVA 
vaccination in national immunization programmes,
13
 RVA vaccine is yet to be introduced into 
the routine immunization in Nigeria but is available in private health sector. Due to the high 
poverty level in the country, use and impact of the vaccine are negligible. 
In preparation for vaccine introduction, many countries initiated surveillance for RVA to 
document disease burden, to describe the epidemiology and to monitor circulating RVA 
strains in the respective countries.
14
 However, updates on currently circulating RVA strains in 
Nigeria is scarce. RVA surveillance is critical to determine the burden of disease due to RVA 
and the characteristics of the RVA strains circulating in Nigeria. This will serve as baseline 
data against which the impact of RVA vaccines can be assessed when eventually introduced 
in Nigeria. This information will be useful to guide policy decision making on RVA vaccine 
introduction. 
This study therefore seeks to describe the epidemiology and strain diversity of RVA among 
children (<5 years) in Ile-Ife, Nigeria before the national introduction of vaccine in the 
country, and also analyzes RVA infection with respect to available clinical/socio-
demographic data. 
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Material and Methods 
Ethics Approval 
Permission to conduct this study was sought from the Obafemi Awolowo University Complex 
Teaching Hospital (OAUTHC) Research Ethics Committee (OAUTHC REC) of the Obafemi 
Awolowo University Ile-Ife, Nigeria (ERC/2012/10/2).  
 
Study Population and Sample Collection 
The study was conducted from August 2012 to December 2013 at the OAUTH 
Comprehensive Health complex, Ile-Ife as well as the only two State Hospitals within Ile-Ife 
(State Hospital, Oke-Ogbo and Health Centre, Enuowa). Children, <5 years who presented 
with diarrhea (3 or more watery stool over a 24hr period, with or without fever, vomiting or 
dehydration) at the outpatient clinics or admitted to the wards and whose parent signed 
informed consent form were eligible for inclusion in the study. Demographic data (age, sex), 
clinical and risk factors (symptoms, source of drinking water, six month exclusive breast 
feeding, stool description, knowledge about RVA etc. were collected through the use of 
questionnaire completed by the parent or guardian of the children. 
RNA Extraction  
The fecal specimens collected were prepared as 10% fecal suspensions in phosphate-buffered 
saline (pH 7.0) for viral RNA extraction, vortexed for 15 min and then centrifuged for 10 min 
20,000 x g. Viral RNA was extracted using the QIAamp Viral RNA Mini Kit according to the 
manufacturer’s instructions (QIAgen Hilden, Germany) on QIAgen Qiacube machine 
according to manufacturer’s protocols. A total of 60 µl of purified viral RNA was obtained 
and stored at -20
o
C until further analysis. 
 
Denaturation, RT and Virus Detection by Quantitative Reverse Transcription Real Time PCR 
Denaturation at 95
o
C for 1 min followed by chilling immediately on ice for about 2 min was 
performed on 2.2 µl RNAse free water and 2.6 µl RNA template mixture. Reverse 
transcription and quantitative real time polymerase chain reaction (qRT-PCR) specific for 
NSP4 of RVA was then carried out in a single-step approach using SuperScript III/Platinum 
Taq OneStep kit (Invitrogen, Carlsbad, CA, USA) according to manufacturer’s instruction. 
Briefly, 8.3 µl master mix was placed into all the wells of 96 well micro plate. Master mix 
contained buffer, RVA sense (5’-GCTTTTAAAAGTTCTGTTCCGAG) and antisense (5’-
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ACTCAATGTGTAGTTGAGGTCGG) primers, RVA probe (5’-VIC-
ATCTTTCCGCACGC-MGB) and Platinum Enzyme mix. Then, 3.7 µl denaturated template 
was added. The reaction plate was placed into a LightCycler® 480 device (Roche, Mannheim, 
Germany) and cycling conditions were as follows: 15 min 50
°
C, 2 min 95
°
C [15 sec 94
 °
C, 32 
sec 55
 °
C] 45 cycles. The efficiency of the RT and the qRT-PCR was evaluated by control 
RNA (RVA positive control, internal control RNA from MS2 phage) and DNA (plasmids 
dilutions containing the respective PCR target sequence). The qRT-PCR assay displayed a 
dynamic range from 10
1
 to 10
6
 target copies with a detection limit of 20 plasmid DNA copies 
per reaction whereas the analytic sensitivity of the PCR for weak positive RNA-dilutions was 
95.2%. For the determination of the reproducibility, intra- and inter-assay variability was done 
using isolated RNA of patients’ feces. The range of the inter-assay Ct-values varied with 
coefficients from 0.58% to 6.12% in correlation to the sample, the overall coefficient of intra-
assay variation was between 1.54% and 5.53%. The analytic specificity was 100%.  
All RVA positive samples from qRT-PCR were subjected to G and P typing. 
 
Rotavirus G and P typing 
Samples pretested by qRT-PCR were genotyped as previously described using published 
methods and primers.
15,16
 Briefly, G and P type-specific amplification of VP7 and VP4 
fragments was performed in two separate PCR assays using QIAgen One-step RT-PCR kit 
(QIAgen, Hilden, Germany). For the first round PCR primers used were VP7-F and VP7-R 
for the VP7 gene while VP4-F and VP4-R were used for the VP8* region of the VP4 gene. A 
second semi-nested multiplex PCR was performed using  G1-, G2-, G3-, G4-, G8-,G9-, G10- 
and G12-specific sense primers for G types, while P-typing included P[4]-, P[6]-, P[8]-, P[9]-, 
P[10]-, and P[11]-specific antisense primers together with VP7-R and VP4-F, respectively. 
Cycling conditions were used as published previously.
16
 For first quality control, the PCR 
products were visualized by electrophoresis on 1.5% agarose gel, stained with GelRed DNA 
stain (Biotium, Hayward, USA) on a BioDocAnalyze Live device (Biometra, Göttingen, 
Germany). For high resolution fragment length analysis, a ABI 3500xL Dx device and 
GeneMapper 5 software (Applied Biosystems, Foster City, USA) were used. All results were 
subsequently verified by sequencing of the VP4 and VP7 fragments. 
 
ELISA 
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In addition to characterization by PCR methods, rotavirus antigen detection of all samples 
was performed by ELISA using RIDASCREEN® Rotavirus kit (R-Biopharm, Darmstadt, 
Germany) according to manufacturer’s instruction. Briefly, a disposable pipette was used to 
aspirate 1 ml RIDASCREEN® sample dilution buffer and added to a sample of stool (approx. 
100 µl). The stool suspension was aspirated and homogenized. Thereafter, 100 µl of the 
positive control, the negative control and the stool sample suspension were added to 
appropriate wells. Subsequently, 100 µl of biotin-conjugated antibody was added and mixed 
by tapping lightly on the side of the plate which was then incubated for 60 min. at room 
temperature. The plate was washed 5 times with the use of a microplate washer. A second 
incubation for 30 min. at room temperature was done after the addition of 100 µl conjugate 2 
and the washing process was repeated. A third incubation for 15 min. in darkness at room 
temperature was carried out later. Lastly, 50 µl stop reagent was added and the result was read 
on an ELISA plate reader at dual wavelengths of 450/620 nm.  
 
 
Nucleotide Sequencing 
For sequencing of VP4 and VP7 genes, the first round PCR products and primers were used. 
The PCR product was cleaned up using EXOSAP-IT (USB Corporation, United States). For 
this, 5 µl PCR product were mixed with 2 µl EXOSAP-IT and incubated at 37
°
C for 15 min. 
The EXOSAP-IT reaction was then inactivated by heating to 80
o
C for 15 min. Purified PCR 
products were sequenced based on Big Dye 3.1 chemistry (Applied Biosystems, Foster City, 
USA), using 0.5 µl primer (10 µM), 1 µl BigDye and 1.5 µl buffer each with the following 
cycling profile: 1 min 96
o
C, [30 sec 96
o
C, 15 sec 50
o
C, 4 min 60
o
C] 25 cycles. 
 
Sequence Analysis of the VP7/VP4 RVA Genes 
Sequencing raw data files were analysed and edited manually using Sequencher 5.2.4 
software (Genecodes). The web-based automated RVA genotyping tool, RotaC 2.0, available 
at http://rotac.regatools.be, was used for quick assignment and confirmation of genotype of 
the study strains.
17
  
 
The sequences were also compared to GenBank reference strains using the Basic Alignment 
Search Tool (BLASTn) analysis to screen for related strains, which were included in 
subsequent phylogenetic analysis. Multiple sequence alignments were created using Geneious 
version 8.1 (Biomatters, Auckland, New Zealand). Phylogenetic analysis was performed 
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using MEGA6 with the Hasegawa-Kishino-Yano substitution model and maximum-
likelyhood method to infer phylogenetic relationships among relevant strains. Bootstrapping 
included 500 replicates. The respective trees with the highest log likelihoods were selected. 
Initial tree(s) for the heuristic search were obtained by applying the Neighbor-Joining method 
to a matrix of pairwise distances estimated using the Maximum Composite Likelihood (MCL) 
approach. A discrete Gamma distribution was used to model evolutionary rate differences 
among sites. The rate variation model allowed for some sites to be evolutionarily invariable. 
The methods and parameters were chosen considering model testing available in MEGA6 
with the options as follows: automatic neighbor joining tree, substitution type: nucleotide, 
gaps: complete deletion, all codon positions, branch swap filter: very strong. The same 
models for VP8* and VP7 were chosen based on lowest Bayesian Information Criterion 
values.  
. 
The partial nucleotide sequences for the VP7 and the VP4 genes were submitted to GenBank 
(accession numbers KT952018-KT952047). 
 
 
Statistical analysis 
The RVA positive and negative specimens were compared in terms of gender, age group, 
seasonal distribution and risk factors by use of chi-square and Fischer exact tests, using two-
tailed significance. SPSS version 20.0.1 for Windows was used for statistical analysis. 
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Results 
Prevalence of Rotavirus Infection 
A high prevalence of RVA infection was observed during the study. From the 103 children 
with diarrhea included in the study, 49 (47.6%) were positive for RVA by qRT-PCR method. 
In 27 samples (26.2%) RVA genome concentrations between 9×10
6
 and 1.3×10
11
 genome 
equivalents (GE) per ml stool suspension were measured. The remaining 22 samples (21.4%) 
contained quantities that were at least two orders of magnitude lower (between 4.5×10
2
 and 
5.7×10
4
 GE per ml stool suspension). Comparison of the viral load with ELISA results shows 
that 26 out of the 27 RVA positive samples with high RVA genome concentration were RVA 
antigen positive by ELISA while all the 22 samples containing lower RVA concentration 
were RVA antigen negative by ELISA. 
 
Rotavirus genotypes 
Notably, 16 (32.7%) of the 49 RVA positive children were infected with RVA G12P[8], with 
one being a mixed infection (see table 1). This is 51.6% of the 31 samples for which G types 
could be determined. All of the G12 strains were associated with P[8]. Among the P types 
observed in the study, P[8] was the most frequent with 61.2% (30/49) detection rate (81.1% of 
the 37 for which P types could be determined), followed by P[6] (n=4; 8.2%) and P[4] (n=2; 
4.1%).  
 
RVA prevalence by age and gender  
None of the children enrolled was found to be up to 5 years of age. RVA infection was more 
prevalent in children less than one year compared with children older than one year (P 
=0.026; Table 2). Children in the age group 0-6 months accounted for 44.9% of the total RVA 
infection (22/49) followed by age group 6-11 months with 36.7% (18/49). Of note is the fact 
that 81.6% (40/49) of the total RVA infection occurred in children less than 1 year. Of the 103 
children included in the study, 51 were female and 52 were male, RVA prevalence by sex was 
44.9% and 55.1%, respectively (Table 2). 
 
Temporal distribution of RVA infection 
RVA infection was detected continuously in a 6-month period lasting from August through 
January but infections increased most rapidly and sharply during October to January which 
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corresponded with the dry season in Nigeria (Figure 1). In January, the RVA prevalence was 
100% though the total sample collected for the month was limited. Samples were not 
collected between February 2013 and July 2013 due to intermittent strike by health workers 
which made the parents not to visit hospital regularly and when they did, they usually came 
for ailments other than diarrhea. 
 
Patient characteristics 
Table 3 shows the clinical details of the patients as provided on the questionnaire by the 
parent/guardian. Only the the group of 27 samples with higher RVA genome concentrations 
(>10
6
 GE/ml stool suspension) was included in this analysis. The 22 samples with low 
quantities (<10
5
 GE/ml stool suspension) were excluded. Generally, knowledge about RVA 
seems to be lower than expected as only 55.7% of the parents know about the virus. However, 
there is no statistical significance between knowledge about RVA and RVA infection (P= 
0.22). The data shows that RVA positive stools were either watery (55.8%; n= 29/52), loose 
(50%; n=7/14), mucoid (40%; n=8/20) but not bloody (0%; n 0/2). Majority (73/103) of the 
children were breastfed exclusively for six month. The RVA infected children had mild, 
moderate or severe dehydration. Mild or moderate dehydration was also found in few RVA 
negative children, however the few cases of severe dehydration were found to be associated 
with RVA infection (100%; n=4). There was neither statistical correlation between RVA 
prevalence and level of maternal education, nor source of drinking water (P= 0.33 and 0.26 
respectively).  
 
Phylogenetic analysis of the VP4 and VP7 
In the present study the sequences of the VP4 (n=37, 505 nucleotides sequence length within 
VP8*) and VP7 (n=32; 715 nucleotides sequence length) PCR products of the RVA positive 
specimens were analyzed. Only the 31 samples (including 1 mixed infection) that were 
successfully sequenced in both genome regions, were included in the phylogenetic trees, 
corresponding with 32 VP7 (figure 2) and 32 VP4 (figure 3) sequences. RVA positive 
samples that could not be sequenced in one or both genome regions had much lower 
viralconcentrations (median: 2x10
3 
genome equivalents/ml stool suspension) compared to 
samples with sequences from both regions (median: 6x10
8 
genome equivalents/ml stool 
suspension), rather reflecting the limit of sensitivity than a lack of specificity. Distribution of 
G and P types was not biased between higher or lower RVA genome concentrations. 
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The VP7 sequences of the G2 and G9 strains segregated into two different clusters according 
to the P type associated with them (P[6] vs. P[4] or P[8] vs. P[4], respectively). A similar 
pattern of clustering was observed among the P[6] sequences: The 3 VP4 sequences of the  
G2P[6] strains (0990, 1049 and 1075) clustered in a separate group form that associated with 
the G3 (1089). There was no distinct clustering among the P[8] sequences corresponding to 
the G type association (G12 vs G9). All of the VP7 sequences derived from the G12 strains 
were found in the same lineage (lineage 3). Most of the G12 sequences from this study were 
closely related (≥99% identity) with sequences from strains MRC-DPRU5144 from Togo and 
R27 from a rural community in Nigeria [Japhet et al., 2012], which were detected in samples 
from 2010 and 2011, respectively. However, the G12 sequence of RVA/Human-wt/NGA/14-
G1048/2013/G12G2P[6]P[8] was more similar to other strains from Sub-Saharan Africa 
(RVA/human-wt/BFA/BF74/2011/G12P[8], RVA/Human-wt/CMR/ES283/2010/G12P[6],  
RVA/Human-wt/NGA/R54/2010/G12P[8], RVA/Human-wt/TGO/MRC-
DPRU5171/2010/G12P[8]) and also shared ≥99% identity with sequences from France, India 
and the United States. While RVA/Human-wt/NGA/14-G1034/2013/G9P[4] was clustered 
with strains from Kenya, Mauritius and Lebanon, most G9 sequences from the present study 
were more closely related to RVA/human-wt/PAK/NIBGE-42/2010/G9P[8] from Pakistan. 
Similarly, one of the G2 sequences (RVA/Human-wt/NGA/14-G0999/2013/G2P[4]) clustered 
separately from the G2P[6] strains, which were similar to different strains from Africa. In 
contrast, the G2P[4] strain did not cluster with African strains but with strains from 
Bangladesh, Belgium and the United States. Sequences similar to the G3 strain RVA/Human-
wt/NGA/14-G1089/2012/G3P[6] were found in Nigeria, Ethiopia, Belgium, Italy and the 
United States.  
The P[8] sequences were much more divergent showing 86.6 - 100% nt identity among each 
other, with sequences clustering in lineages 3 and lineage 4. G9 strains from the present study 
were found in both, P[8] lineage 3 and 4. Sequences of all other P types and of all G types 
clustered within the same lineage of their respective genotype. The P[6] sequences clustered 
with strains from Nigeria, South Africa and the United States. Regarding P[4],  RVA/Human-
wt/NGA/14-G1034/2013/G9P[4] and RVA/Human-wt/NGA/14-G0999/2013/G2P[4] were 
found in two different clusters with strains from Asia but none from Africa. In contrast, most 
P[8] sequences were closely related to sequences from strains from Nigeria, Togo, South 
Africa, Belgium and the United States. The OP354-like sequences (lineage 4) clustered with 
strains from Nigeria, South Africa, India and Belgium.  
The derivative VP8* amino acid sequences of the OP354-like P[8] strains from this study 
showed several changes in antigenic epitopes compared to RV1 and RV5, with S145G, 
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N149S, S187G, A191S, N192D and N194T in epitope 8-1, R182G in epitope 8-2, and N113D 
in epitope 8-3 (residue numbering based on vaccine strains). The derivative VP7 amino acid 
sequence of G2 strains differed from the RV5 G2 strain in epitopes 7-1a (A87T, D96A, 
N130D) and 7-1b (S213) with strain 14-G0999 having additional amino acid changes in 
epitope 7-1a (N130D) and 7-1b (S242N). The G3 strain 14-G1089 differed in epitope 7-1b 
(K238N, D242N) and 7-2 (A146V, A 221D) from the RV5 G3 strain. 
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Discussion 
In the present study, the diversity of the circulating RVA strains in children with diarrhea in 
Ile-Ife, a South-western part of Nigeria, before national vaccine introduction was analyzed. 
Furthermore, the correlation between clinical/sociodemographic factors and rate of RVA 
infection among the study population was examined. 
A high prevalence of RVA G12P[8] strains with close relation to strains from other Sub-
Saharan countries was observed and this made up half of the RVA positive samples identified 
in this study. Since its first detection in the Philippines in 1987, G12 strains have been 
detected in many parts of the world and may be regarded as the sixth most important human 
genotype.
18-20
 Furthermore, G12 strains have been found with high frequency in most of the 
recent African studies.
12,21,22
 Of note is the fact that all the G12 strains observed in this study 
were associated with P[8] exclusively. Most African G12 isolates are G12P[8] 
19,23,24
 and 
more recent studies show increasing number of G12P[8].
20,25,26
 Detection of G12P[8] is also 
common with studies from the USA and Europe.
27-29
  
In addition to G2P[4], also G2P[6] was detected which is in accordance with previous data 
from African countries but contrary to studies from  Europe and the Americas where the 
G2P[4] genotype combination is highly predominant and G2 with P[6] is 
unusual.
19,20,23,24,27,30,31
 This difference was also reflected in the present study by the VP4 and 
VP7 sequences of RVA/Human-wt/NGA/14-G0999/2013/G2P[4] that were most similar to 
strains from Asia and Europe, while the VP4 and VP7 sequences of G2P[6] were closely 
related to African strains.  
Genotype P[8] exhibited a high diversity, with sequences clustering in two different lineages. 
While the P[8] sequences of the G12 and some G9 strains belonged to lineage 3, the OP354-
like sequences in lineage 4 comprised only G9 strains. This may possibly have been due be a 
recent reassortment, since some G9 sequences were identical despite of their differential 
association with P[8] lineage 3 and lineage 4 sequences (e.g. 10-G1059 and 10-G1061). 
However, no sequence data on other genome segments was available for further analysis of 
the possible reassortant strains. 
Compared to RV1 and RV5, the amino acid changes in antigenic epitopes of OP354-like 
strains, G2 strains and the G3 strain found in the present study were also detected in studies 
from Brazil, Belgium, Nicaragua and Tunisia.
32-35
 While some of the amino acid changes are 
known to escape neutralization by monoclonal antibodies,
36
 an impact on the protection by 
the vaccines has not been shown.  
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Among the strains usually associated with most infections in children globally, G1 and G4 
strains were not detected in this study while only one G3 and five G2 were detected. The 
second most common circulating strain in this study was G9. G8 strains which were detected 
with high frequency in earlier African studies 
19,20,37
 were not detected in this study, nor in 
other recent studies in Africa, seemingly coinciding with the increase in detection of G12 
strain in the African continent. This shift has been observed with and without rotavirus 
immunization programs, and therefore the evidence suggests that it represents natural 
genotype distribution fluctuations, and is not related to vaccine introduction.  
 
Genetic diversity is recognized to be generally greater in developing countries than in 
industrialized countries.
37-39
 The heterogeneity of strains leading to high inter- and 
intragenotypic divergence, as observed with G2, G9 and P[8] in the present study, emphasizes 
the need for regular G and P typing and sequencing, which should not be seen as multiplicity 
of data, but a vital information to determine the heterogeneity of circulating strains which may 
have implication for the vaccine efficacy (VE) in the long term. Both available vaccines, RV1 
and RV5, have comparable efficacy and confer significant degree of cross protection against 
heterotypic strains.
40
 Despite this, there is evidence from both developed and developing 
countries, that VE is lower against some heterotypic strains, and in particular early assessment 
following the roll out of RV1 in Malawi suggests that VE is lower against G2 and G12 strains 
than against G1 strains.
41
 An influence of vaccination on circulating RVA genotypes has also 
been reproduced in mathematical models that consider a combination of natural and vaccine-
induced immunity against homo- and heterotypic strains, and explain observed changes after 
introduction of mass vaccination.
42
 Therefore strain surveillance before and during the 
implementation of mass vaccination programs remains important in order to verify and fully 
understand this phenomenon. Over time, significant drifts or shifts in strain distribution may 
result in changes in the efficacy of the vaccination programs and may result in real or 
perceived fears of increases in vaccine failures. 
 
In this study, a correlation between RVA infection and age (P= 0.026) was found. Majority of 
the RVA infections occurred in children <1 year compared with children >1 year, in 
agreement with other reports from the region 
10,12,43-46
 and data from the African Rotavirus 
Surveillance Network.
19
 Nigeria, like many other African countries have two main seasons in 
a year, namely wet (warm, rainy) and the dry (cool, dry months) seasons. An increase of RVA 
within the dry season was observed in this study supporting previous findings from the few 
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data available on the seasonal pattern of RVA infection in West Africa and specifically in 
Nigeria.
10,12,44,47
 
 
Considering the importance of RVA and the fact that almost every child by the age of 3 to 5 
years will have been infected by the virus, there is the need for RVA awareness in Nigeria, 
since only about half (55.6%) of the respondents have knowledge about RVA. Awareness of 
the importance of RVA could probably increase the number of parents that will be ready to 
pay for the RVA vaccine which is available in private health sector but the use and the impact 
in the country are negligible due to the high poverty level in the country. No difference is 
observed in the proportion of RVA infection between children breastfed exclusively for six 
months and those bottle fed; however, possibility exists that breastfeeding reduced the 
severity of the diarrhea since 70.8% (n=73/103) of the mothers breastfed their children for the 
first six months of life during which maternal antibodies would have been transferred 
although not able to prevent infection. Previous studies have also suggested that the passive 
protective effect of maternal antibodies, transferred through placenta or through breast milk, 
may have role against RVA infection, at least during early months of breastfeeding.
48,49
 
However, further studies with larger population size and where breastfeeding is not common 
is needed to confirm this observation. 
 
Previous studies have reported correlation between ELISA and real time PCR results 
50-54
 and 
low Ct-values (high viral load) being related to more severe disease.
55
 While ELISA and PCR 
results overall appear to be useful to screen populations for vaccine effectiveness, samples 
from patients with AGE that were positive in qRT-PCR but negative by ELISA did not show 
a significant correlation.
52
 This is likely due to the fact that RVA vaccination efficiently 
reduces cases of severe disease.
56
 but does not completely prevent infection, similar to natural 
rotavirus infections.
57
 This would explain why the percentage of cases with low RVA genome 
concentrations in vaccinated children with AGE were not significantly lower than in 
unvaccinated healthy children.
52
 Supported by the high proportion of samples with low levels 
of RVA shedding in the present study, a significant bias appears to be likely when PCR 
results are interpreted without considering genome concentration or additional antigen testing. 
This corroborates data from Malawi on the use of qRT-PCR to distinguish symptomatic and 
asymptomatic rotavirus infections.
58
 
 
The main limitations of the present study are the small sample size and the incidental 
interruption of sample collection in the first half of 2013. No data on the onset of diarrhea 
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were available which would have helped to identify samples where the cause of low RVA 
genome concentrations could have been sampling at the end of the acute phase when RVA 
shedding might have decreased already. In other cases, low RVA quantities of <10
5
 GE/ml 
stool suspension (cycle threshold >30 in the present qRT-PCR), could indicate asymptomatic 
RVA infection 
58,59
 and the involvement of a different aetiological agent than RVA. However, 
RVA genotype distribution was not associated with genome concentration and the results 
were broadly in line with other studies from the region, which suggests that there were no 
significant biases. 
 
To conclude, a high prevalence of RVA infections with genotypes G12 and G9 was found in 
the pediatric population with acute gastroenteritis. The common G1-G4 strains were either not 
detected or very few in number. No G1 strain was found, which is of relevance as baseline 
data since different studies have suggested that VE is lower against G2 and G12 strains than 
against G1 strains. Also, the high divergence in P[8] sequences detected in this study and 
changes in antigenic epitopes of some of them compared to RV1 and RV5 may provide 
relevant baseline information for the assessment of effectiveness of RVA vaccination when 
eventually introduced into the Nigerian national immunization program. Furthermore, 
significant bias from asymptomatic cases with low levels of RVA shedding is possible and 
should be considered when interpreting PCR results.  
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Figure 1: Seasonal distribution of RVA from August 2012 to December 2013  
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Figure 2: Phylogenetic tree of the partial VP7 gene (nt position 51- 932) strains from Nigeria (with asterisk, 
sample ID and year of sample collection) and different G type reference strains. The tree was constructed 
using the maximum-likelihood method and HKY substitution model available in MEGA6 (scale bar: nucleotide 
substitutions per site). Reference sequences were obtained from the GenBank database. Reference 
sequences for genotype lineages are printed in italic font. To avoid duplication of sequences in GenBank, 
only representative sequences of different clusters were submitted. G2: KT952018 (14-G0990), KT952019 
(14-G1048), KT952020 (14-G0999), G9: KT952021 (14-G1086), KT952022 (14-G1088), KT952023 (14-
G1085), KT952024 (14-G1017), KT952025 (14-G1034), G3: KT952026 (14-G1089), G12: KT952027 (14-
G1025), KT952028 (14-G1037), KT952029 (14-G1035), KT952030 (14-G1039), KT952031 (14-G1092), 
KT952032 (14-G1048).  
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Figure 3: Phylogenetic tree of the partial VP4 gene (nt position 132- 795) strains from Nigeria (with asterisk, 
sample ID and year of sample collection) and different P type reference strains. The tree was constructed 
using the maximum-likelihood method and HKY substitution model available in MEGA6 (scale bar: nucleotide 
substitutions per site). Reference sequences were obtained from the GenBank database. Reference 
sequences for genotype lineages are printed in italic font. To avoid duplication of sequences in GenBank, 
only representative sequences of different clusters were submitted. P[6]: KT952033 (14-G0990), KT952034 
(14-G1048), KT952035 (14-G1089), P[8]: KT952036 (14-G0992), KT952037 (14-G1085), KT952038 (14-
G1008), KT952039 (14-G1035), KT952040 (14-G1042), KT952041 (14-G1076), KT952042 (14-G1054), 
KT952043 (14-G1048), KT952044 (14-G1086), KT952045 (14-G1088), P[4]: KT952046 (14-G0999), 
KT952047 (14-G1034).  
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Table 1: Distribution of G and P genotype combination of RVA strains detected among 
children (0-5years) with gastroenteritis in Ile-Ife, Nigeria. 
 
Rotavirus genotype 
 
  
No. (%) of strains 
 P[4] P[6] P[8] P[8] P[6] 
(mixed) 
P n/t Total 
 
 
G2   
G3  
G9  
G12  
G2/G12 (mixed) 
G n/t  
Total  
 
1  
0   
1  
0   
0   
0  
2 (4.1) 
 
 
3  
1  
0  
0  
0  
0  
4 (8.2) 
 
0  
0  
9  
15  
0  
6  
30 (61.2)
  
 
0  
0  
0  
0  
1  
0  
1 (2.0)  
 
0 
0 
0 
0 
0 
12 
12 (24.5) 
 
 
4 (8.2) 
1 (2.0) 
10 (20.4) 
15 (30.6) 
1 (2.0) 
18 (36.7) 
49(100) 
 n/t= not typeable 
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Table 2: Age and Sex Profile of RVA Infection 
Characteristics RVA detected RVA Not detected Total 
 (a) Age 
<6 months  
6-11 months  
1-2 years  
3-4 years  
Total   
(b) Sex 
Male   
Female  
Total   
 
 22  
 18  
 7  
 2  
 49  
 
 27 
 22  
 49  
 
 13  
 28  
 11  
 2  
 54  
 
 24  
 30  
 54 
  
 
35 
46 
18 
4 
103 
 
52 
51  
103  
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Table: 3 Clinical/sociodemographic factors and Rotavirus infection 
Clinical characteristics/manifestation RVA positive (%) RVA negative (%) Total (%) 
(a) Source of Drinking water 
Well      
Tap      
Bore hole    
Sachet water     
Bottled water     
Rain      
 Total                                                                
(b) Stool description 
Watery      
Loose      
Mucus      
Bloody 
No data     
 Total                                                                
(c) Symptoms (diarrhea with) 
Mild or no dehydration   
Moderate dehydration with/without vomiting 
Severe dehydration with/without vomiting  
Total                                                              
(d) Level of maternal Education 
None 
Low      
Middle      
High 
No data     
 Total                                                            
(e) Knowledge about RVA 
Yes      
No 
No data     
 Total   
(f) 6 month exclusive breastfeeding  
Yes      
No      
Not sure   
Total   
 
14 (48.3)  
  4 (21.1)  
  1 (11.1)  
  7 (36.8)  
  0 (0.0)  
  1 (33.3)  
27 (33.3) 
  
16 (41.0)  
  5 (41.7)  
  4 (25.0)  
  0 (0.0)   
 2 (15.4) 
27 (33.3) 
 
16 (24.6)  
  9 (64.3)  
  2 (100)  
27 (33.3) 
 
  0 (0.0) 
  4 (44.4)  
12 (40.0)  
  7 (20.0)  
  4 (80.0) 
27 (33.3) 
 
13 (28.9) 
12 (37.5) 
  2 (50.0) 
27 (33.3) 
 
21 (36.2) 
  2 (33.3) 
  4 (23.5) 
27 (33.3) 
 
15 (51.7) 
15 (78.9) 
  8 (88.9) 
12 (63.2) 
  2 (100) 
  2 (66.7) 
54 (66.7) 
 
23 (59) 
7 (58.3) 
12 (75.0) 
1 (100) 
11 (84.6) 
54 (66.7) 
 
49 (75.4) 
  5 (35.7) 
  0 (0.0) 
54 (66.7) 
 
  2 (100) 
  5 (55.6) 
18 (60.0) 
28 (80.0) 
  1 (20.0) 
54 (66.7) 
 
32 (71.1) 
20 (62.5)  
  2 (50.0) 
54 (66.7) 
 
37 (63.8) 
  4 (66.7) 
13 (76.5) 
54 (66.7) 
 
29 (35.8) 
19 (23.5) 
 9 (11.1) 
19 (23.5) 
 2 (2.5) 
 3 (3.7) 
81 (100) 
 
39 (48.2) 
12 (14.8) 
16 (19.8) 
  1 (1.2)  
13(16.0) 
81(100) 
 
65 (80.2) 
14 (17.3) 
  2 (2.5)  
81 (100) 
 
  2 (2.5) 
  9 (11.1) 
30 (37.0) 
35 (30.8) 
  5 (6.2) 
81 (100) 
 
45 (55.6) 
32 (39.5) 
  4 (4.9) 
81 (100) 
 
58 (71.6) 
  6 (7.4) 
17 (21.0) 
81 (100) 
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